^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Basal Cell Carcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
Published date:
08/12/2019
Excerpt:
Histologies that were TMB-high included melanoma (N = 6), bladder cancer (N = 2), cutaneous squamous cell carcinoma (N =2), glioblastoma (N = 1), breast cancer (N = 1), basal cell carcinoma (N = 1), esophageal carcinoma (N = 1), and prostate cancer (N = 1)...All patients were treated with either PD-1/L1 or CTLA4 checkpoint blockade (some received a combination of these agents)...The median PFS for TMB-high tumors compared to TMB-Low to -Intermediate tumors was 26.8 months vs. 4.3 months. (P = 0.0173, HR 0.42 [95% CI 0.22–0.77])...
DOI:
10.1158/2326-6066.CIR-19-0149
Test:
